Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Quanta Therapeutics Inc.
Headquarters: San Francisco, CA, United States of America
Website: https://www.quantatx.com/
Year Founded: 2018
Status: Private
BioCentury | Sep 22, 2023
Distillery Therapeutics
Noncovalent inhibitor targeting multiple KRAS mutations in cancer
BioCentury | May 22, 2023
Deals
May 22 Quick Takes: Ironwood building GI franchise via $1B VectivBio acquisition
Plus: Krystal raises $160M PIPE and updates from Avrobio-Novartis, Avidity, BMS, Hepion, Rain, Blueprint
BioCentury | Apr 25, 2023
Product Development
KRAS’s next chapter: hitting the target’s active form
Investors rewarded Revolution for preclinical KRAS (ON) data at AACR23, as a wave of dual KRAS (ON/OFF) inhibitors at the meeting gear up for the clinic
BioCentury | Dec 14, 2022
Management Tracks
Quanta names Exelixis alum Faoro as CMO
Plus: Abingworth adds Joy Ghosh as managing director and Renibus hires Ramdas as SVP
BioCentury | Oct 27, 2021
Product Development
Oct. 26 Quick Takes: CD8 Treg modulating play Mozart debuts with $55M
Angion, Cortexyme post Phase III misses, plus DNA Script, Novartis, Quanta, Exciva and more
Items per page:
1 - 5 of 5